Journal of Cutaneous Medicine and Surgery最新文献_第7页

Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab. 阿达木单抗治疗反应欠佳的化脓性汗腺炎患者的治疗药物监测。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-05-23 DOI: 10.1177/12034754251341846

Hannah Stirton, Raed Alhusayen

{"title":"Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab.","authors":"Hannah Stirton, Raed Alhusayen","doi":"10.1177/12034754251341846","DOIUrl":"https://doi.org/10.1177/12034754251341846","url":null,"abstract":"Background: Adalimumab is a biologic used in the treatment of hidradenitis suppurativa (HS). Therapeutic drug monitoring (TDM) has emerged as a potential strategy to optimize treatment efficacy, yet its utility in HS remains underexplored. Our aim was to assess the utility of TDM in HS patients with suboptimal adalimumab response by investigating the prevalence of antidrug antibodies and subtherapeutic drug levels.Methods: A cross-sectional study of 62 patients with suboptimal response to adalimumab was conducted at a dermatology clinic in Toronto, Ontario. Data on adalimumab serum trough levels, autoantibody status, and demographics were collected. Patients were divided into therapeutic (≥10.6 μg/mL) and subtherapeutic (<10.6 μg/mL) drug categories based on trough level.Results: Of 51 patients on adalimumab 40 mg weekly, 32 patients (62.7%) had therapeutic drug levels and 19 (37.3%) had subtherapeutic levels. In the 11 patients on adalimumab 80 mg weekly, 7 patients had therapeutic drug levels (28.19 μg/mL) and 4 had subtherapeutic levels (mean 3.26 μg/mL). Autoantibodies were detected in 21.06% of patients with subtherapeutic drug levels on adalimumab 40 mg weekly. There was a significant association between Hurley stage and drug level (P = .015) in patients on adalimumab 40 mg weekly.Conclusions: In HS patients with suboptimal response to standard adalimumab dosing, a significant number of patients have subtherapeutic drug levels with a minority of those having anti-adalimumab antibodies. TDM can be helpful in identifying HS patients with subtherapeutic drug levels and without antidrug antibodies who could potentially benefit from dose escalation.","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251341846"},"PeriodicalIF":3.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Comparative Study of Aluminum Chloride, Oxybutynin Chloride, and Botulinum Toxin in the Treatment of Primary Focal Hyperhidrosis. 氯化铝、氯氧布宁和肉毒毒素治疗原发性局灶性多汗症的比较研究。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-05-21 DOI: 10.1177/12034754251336233

Basma Magdy ElKholy, Samia Ali Ebrahim, Mai Ali Othman Sobh, Rania Alakad, Heba Allah Mohamed Hoseiny

{"title":"A Comparative Study of Aluminum Chloride, Oxybutynin Chloride, and Botulinum Toxin in the Treatment of Primary Focal Hyperhidrosis.","authors":"Basma Magdy ElKholy, Samia Ali Ebrahim, Mai Ali Othman Sobh, Rania Alakad, Heba Allah Mohamed Hoseiny","doi":"10.1177/12034754251336233","DOIUrl":"https://doi.org/10.1177/12034754251336233","url":null,"abstract":"Background: Primary hyperhidrosis (HH) is a common challenging problem. Different treatment modalities are present with no clear evidence favoring one modality over the others.Objectives: To assess and compare the efficacy of aluminum chloride hexahydrate (ACH), oxybutynin chloride, and botulinum toxin type-A (BTX-A) in treating primary focal HH.Patients and methods: Sixty-six patients of both sexes, with primary HH, were equally and randomly divided into 3 groups. Group (A) received a single session of intradermal (BTX-A), Group (B) received topical application of ACH lotion 25% once daily, and Group (C) received oral oxybutynin chloride 10 mg daily for 3 months. The clinical response was assessed using the Hyperhidrosis Severity Scale (HDSS) and the patients were followed up for 6 months.Results: The 3 modalities were effective and safe in the treatment of primary HH, but the clinical response was significantly higher in the BTX-A group (81.8% excellent response) compared to the other 2 modalities. The reduction of hyperhidrosis was also maintained for a longer period in the BTX-A group.Conclusion: Among the 3 modalities, BTX-A was associated with a higher reduction of HDSS scores. A single session was sufficient; however, pain and high cost are limiting factors.","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251336233"},"PeriodicalIF":3.1,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erythema Ab Igne. Igne的红斑。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-05-20 DOI: 10.1177/12034754251341864

Pei-Chun Weng

引用次数: 0

Ackerman's Tumor. 阿克曼的肿瘤。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-05-20 DOI: 10.1177/12034754251341867

Rajat Mittal, Megha Goyal

引用次数: 0

Anal Sarcomatoid Amelanotic Melanoma. 肛门肉瘤样无色素黑色素瘤。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-05-20 DOI: 10.1177/12034754251341868

Fabio Marino

引用次数: 0

Keratoelastoidosis Marginalis of the Hands. 手部边缘类角膜弹性病。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-05-20 DOI: 10.1177/12034754251341865

Yashdeep Singh Pathania, Purva Mehta

引用次数: 0

Outcomes of Isolated Nail Psoriasis Treatment With Roflumilast 0.3% Cream: A Case Series of 7 Patients. 0.3%罗氟司特乳膏治疗孤立性甲癣7例疗效分析

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-05-17 DOI: 10.1177/12034754251339106

Julio Jasso-Olivares

{"title":"Outcomes of Isolated Nail Psoriasis Treatment With Roflumilast 0.3% Cream: A Case Series of 7 Patients.","authors":"Julio Jasso-Olivares","doi":"10.1177/12034754251339106","DOIUrl":"https://doi.org/10.1177/12034754251339106","url":null,"abstract":"Background: Nail psoriasis (NP) is not an uncommon psoriasis variant whose symptoms have a negative impact on patients' quality of life. Treating NP can be a great challenge for the dermatologist, especially when it is presented as isolated subtype or when it is not associated with psoriatic arthritis (PsA). The available treatments, topical or systemic therapies, have limited efficacy and can be associated with adverse effects (AEs). Topical roflumilast is an FDA-approved treatment for skin plaque-psoriasis in patients aged 6 and above, but there is limited evidence for treating NP. We present outcomes of nail psoriasis not associated with PsA treated with roflumilast 0.3% cream in 7 patients.Methods: A single center, retrospective case series analysis was conducted in a Canadian nail clinic in adult patients with NP refractory to treatment between January 2023 and December 2024. Clinical characteristics (matrix and/or nail bed alterations) were included to calculate the Nail Psoriasis Severity Index (NAPSI) score. Improvement degree was based on NAPSI score reduction. All patients were treated with roflumilast 0.3% cream daily for at least 16 weeks.Results: The case series included 7 patients with NP not associated with PsA. The mean baseline NAPSI score was 19, which decreased to 6.8 after 16 weeks of topical treatment. Roflumilast 0.3% cream was used both as monotherapy and/or in combination with topical steroids or acitretin. Interestingly, all patients reported quality of life improvements, and complete lesion clearance was achieved in almost all patients.Conclusions: Topical roflumilast showed promising results to treat topically NP. In this case series topical roflumilast was effective, well-tolerated and not associated with AEs.","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251339106"},"PeriodicalIF":3.1,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SARS-CoV-2 Vaccine Seroconversion in Patients With Hidradenitis Suppurativa Receiving Anti-TNF Therapy. 接受抗肿瘤坏死因子治疗的化脓性汗腺炎患者的SARS-CoV-2疫苗血清转化

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-05-14 DOI: 10.1177/12034754251338809

Peter Y Ch'en, Avigdor Nosrati, McCall E Torpey, Michelle Toker, Zahidul Islam, Kristina L Campton, Steven R Cohen

{"title":"SARS-CoV-2 Vaccine Seroconversion in Patients With Hidradenitis Suppurativa Receiving Anti-TNF Therapy.","authors":"Peter Y Ch'en, Avigdor Nosrati, McCall E Torpey, Michelle Toker, Zahidul Islam, Kristina L Campton, Steven R Cohen","doi":"10.1177/12034754251338809","DOIUrl":"https://doi.org/10.1177/12034754251338809","url":null,"abstract":"Background and objectives: Tumour necrosis factor-α (TNF-α) inhibitors such as adalimumab and infliximab are commonly used in moderate-to-severe hidradenitis suppurativa (HS). While the impact of TNF-α inhibitors on outcomes after an active infection in patients with HS has been explored, their effect on the SARS-CoV-2 vaccine response remains unknown. We investigated the impact of TNF-α inhibitor therapy on the immunogenic response to the SARS-CoV-2 vaccine in patients with HS.Methods: This is a single-centre retrospective chart review of 120 patients with recorded levels of anti-SARS-CoV-2 spike antibody. This cohort was characterized descriptively by demographics, antibody levels, vaccine brand, number of doses, and days elapsed from vaccination. These variables were then compared by usage of anti-TNF therapy. Secondary analyses included comparison by biologic type, time on biologic, and biologic dosage.Results: We found no significant difference in seroconversion following SARS-CoV-2 vaccination while on anti-TNF therapy in HS patients; a finding that holds in comparisons between anti-TNF therapy type, time exposed to biologic, and anti-TNF dosage.Conclusions: Patients with HS on anti-TNF therapy receiving the SARS-CoV-2 mRNA vaccine seroconvert similarly as those without anti-TNF therapy, indicating this population should receive the vaccine and expect a similar degree of protection against COVID-19 compared to HS patients who do not receive anti-TNF therapy.","PeriodicalId":15403,"journal":{"name":"Journal of Cutaneous Medicine and Surgery","volume":" ","pages":"12034754251338809"},"PeriodicalIF":3.1,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Foreign Body Granuloma. 异物肉芽肿。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-05-14 DOI: 10.1177/12034754251341860

Li-Yu Ge, Ze-Hu Liu

引用次数: 0

Drug-Associated Pemphigus Reported by Physicians: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System. 医生报告的药物相关性天疱疮：FDA不良事件报告系统的现实世界药物警戒研究。

IF 3.1 4区医学

Journal of Cutaneous Medicine and Surgery Pub Date : 2025-05-14 DOI: 10.1177/12034754251337371

Jianing Bi, Wenkai Zhang, Yinan Zhang, Qiaochu Chen, Bingnan Cui, Zhanshuo Xiao

引用次数: 0